Pharmaceutical Law & Industry Report® Index-Summary

E-HEALTH

– Collaboration by pharmacy groups, 1258
– E-prescriptions

– Electronic heath records

– – CMS rules, 1436
– – Incentives, BNA webinar, 1000

E-PRESCRIPTIONS

– Controlled substances, DEA rule, 427; interim final rule, 597; concerns raised, 721
– Financial penalties, 1152
– Meaningful use incentives, 862
– Narcotics, Medicare limits, 1371
– Reporting requirements, 1587
– Trends

– – Doubled prescriptions reported, 466
– – Mass. leads states, 1259
– – Physician use studied, 999

– W.Va. Medicaid initiative, 1350

EFFEXOR

– Antidepressant and suicide, learned intermediary (W.D. Pa.), 277
– Generic

– – Intellipharmaceutics application, 634
– – Orgenus generic challenge (D.N.J.), 1398
– – Teva generic approved, 899

– Preemption and suicide warning

– – No preemption of claims (E.D. Pa.), 1184
– – Risk warning and preemption (10th Cir.), 316

EGRIFTA

– AIDS drug application, 728
– Lipodystrophy in HIV patients, 1474

ELLA

– Emergency contraceptive approved, 1094

ELOXATIN

– Approval, stay to end (D.D.C.), 1018
– Generic

– – Cancer drug, infringement by generic (D.N.J.), 384; generic sales blocked, 552
– – Chemo treatment, generic settlement, 452
– – Launch of generic, 370

ENABLEX

– Overactive bladder drug generic, dismissal (D. Del.), 1397

ENFORCEMENT POLICY

– E-rulemaking guidelines, 1517
– Effective compliance programs for firms, Special Report, 695
– Exclusion of CEO from program participation, 1511; preview of things to come, 1559
– Renew scrutiny in 2010, BNA Insights, 299
– Unapproved drugs, FDA warning letters, 365

ENTOCORT

– Crohn disease generic, patent settlement (D. Del.), 643

EPOGEN

– Anemia drug recall, 1258

ERISA

– D.C. PBM law preempted (D.C. Cir.), 913

ESBRIET

– Lung disease drug cleared by FDA panel, 332; no action, 603

EUROPEAN UNION (EU)

– Adverse effect monitoring, 1261
– Antitrust, Citalopram maker under investigation, 75
– Biosimilars draft guidelines, 1530
– Generic drugs

– – Delaying generics, decline in patent settlements, 903
– – India, generic drug seizures, 664; deal with EU, 1382
– – Monetary incentives, 570
– – Raids launched, 1565
– – Seizures in transit, 664

– IMS Health purchase, EU clearance, 171
– Labeling rules, 1530
– Misleading and incorrect data, 1001
– Novartis bid for Alcon, 1067
– Pay-for-delay probes, 75
– Teva purchase of Ratiopharm, 1066

EVAMIST

– Menopause drug, adverse effects on children, 1030

EVISTA

– Osteoporosis drug, generic challenge (S.D. Ind., D. Nev.), 621
– Patent upheld (Fed. Cir.), 1133

EVOXAC

– Dry mouth treatment generic settlement (D. Del.), 1053

EXALGO

– Painkiller generic challenge (D.N.J.), 1621

EXPERT WITNESSES

– Accutane, exclusion of causation evidence (N.J. Super. Ct.), 184
– Baycol and muscle damage, exclusion of expert (8th Cir.), 354
– Metoclopramide and tardive dyskinesia (S.D. W.Va.), 1554
– Neurontin

– – Epilepsy drug and suicide, widow's suit (M.D. Tenn.), 322; expert testimony, 627; settlement, 682
– – No causation (D. Mass.), 1146

– Phenylpropanolamine and neurological ailments (Iowa), 235
– Premarin breast cancer suits (E.D. Ark., D. Minn.), 1219
– Prempro and breast cancer (D.P.R.), 1556
– Trasylol product liability (S.D. Fla.), 1432